title: Reduced folate and serum vitamin metabolites in patients with rectal carcinoma: an open-label feasibility study of pemetrexed with folic acid and vitamin B12 supplementation.
abstract: The objectives of this single-center, open-label, phase II study were to evaluate (a) the feasibility and safety of neoadjuvant administration of pemetrexed with oral folic acid and vitamin B12 (FA/B12) in newly diagnosed patients with resectable rectal cancer and (b) intracellular and systemic vitamin metabolism. Patients were treated with three cycles of pemetrexed (500 mg/m, every 3 weeks) and FA/B12 before surgery. The reduced folates tetrahydrofolate, 5-methyltetrahydrofolate, and 5,10-methylenetetrahydrofolate were evaluated from biopsies in tumor tissue and in adjacent mucosa. Serum levels of homocysteine, cystathionine, and methylmalonic acid were also measured. All 37 patients received three cycles of pemetrexed; 89.2% completed their planned dosage within a 9-week feasibility time frame. Neither dose reductions nor study drug-related serious adverse events were reported. Reduced folate levels were significantly higher in tumor tissue compared with adjacent mucosa at baseline. After FA/B12 administration, tissue levels of reduced folates increased significantly and remained high during treatment in both tumor and mucosa until surgery. Serum levels of cystathionine increased significantly compared with baseline after FA/B12 administration, but then decreased, fluctuating cyclically during pemetrexed therapy. Homocysteine and methylmalonic acid levels decreased significantly after FA/B12 administration, and remained below baseline levels during the study. These results indicate that administration of three neoadjuvant cycles of single-agent pemetrexed, every 3 weeks, with FA/B12 in patients with resectable rectal cancer is feasible and tolerable. Tissue and serum vitamin metabolism results demonstrate the influence of pemetrexed and FA/B12 on vitamin metabolism and warrant further study.
authors.affiliation: aLilly Deutschland GmbH, Bad Homburg, Germany bSahlgrenska University Hospital, Östra cAbbVie, Uppsala, Sweden.
authors.forename: Clemens C
authors.initials: CC
authors.lastname: Stoffregen
authors.forename: Elisabeth A
authors.initials: EA
authors.lastname: Odin
authors.forename: Göran U
authors.initials: GU
authors.lastname: Carlsson
authors.forename: Göran K
authors.initials: GK
authors.lastname: Kurlberg
authors.forename: Hillevi G
authors.initials: HG
authors.lastname: Björkqvist
authors.forename: Maria T
authors.initials: MT
authors.lastname: Tångefjord
authors.forename: Bengt G
authors.initials: BG
authors.lastname: Gustavsson
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003540:Cystathionine / Q000097:blood; D005240:Feasibility Studies; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage / Q000378:metabolism*; D005493:Folic Acid Antagonists / Q000627:therapeutic use*; D006710:Homocysteine / Q000097:blood; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism; D008297:Male; D008764:Methylmalonic Acid / Q000097:blood; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D000068437:Pemetrexed / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D012007:Rectum / Q000378:metabolism; D014805:Vitamin B 12 / Q000008:administration & dosage / Q000097:blood*
chemical_list: D000970:Antineoplastic Agents; D005493:Folic Acid Antagonists; D000068437:Pemetrexed; D006710:Homocysteine; D003540:Cystathionine; D008764:Methylmalonic Acid; D005492:Folic Acid; D014805:Vitamin B 12
references.citation: J Clin Oncol. 2012 Nov 1;30(31):3827-33
references.pmid: 23008301
references.citation: Biomed Res Int. 2013;2013:389046
references.pmid: 23984356
references.citation: Mol Med. 2015;21:597-604
references.pmid: 26193446
references.citation: Ann Oncol. 1999 Oct;10(10):1175-9
references.pmid: 10586333
references.citation: Semin Oncol. 1999 Apr;26(2 Suppl 6):11-23
references.pmid: 10598550
references.citation: Semin Oncol. 1999 Apr;26(2 Suppl 6):42-7
references.pmid: 10598554
references.citation: Cancer. 2000 Apr 15;88(8):1807-13
references.pmid: 10760756
references.citation: Clin Cancer Res. 2000 Sep;6(9):3687-95
references.pmid: 10999762
references.citation: Clin Chem Lab Med. 2001 Aug;39(8):739-46
references.pmid: 11592444
references.citation: Mol Cancer Ther. 2002 May;1(7):545-52
references.pmid: 12479273
references.citation: Vitam Horm. 2003;66:403-56
references.pmid: 12852262
references.citation: J Clin Oncol. 2003 Jul 15;21(14):2636-44
references.pmid: 12860938
references.citation: Colorectal Dis. 2003 Sep;5(5):406-15
references.pmid: 12925071
references.citation: Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):6012-9
references.pmid: 14676127
references.citation: J Clin Oncol. 2004 May 1;22(9):1589-97
references.pmid: 15117980
references.citation: Biochem Pharmacol. 1989 Jan 15;38(2):335-42
references.pmid: 2914018
references.citation: Cancer Res. 1992 Jan 1;52(1):36-44
references.pmid: 1370075
references.citation: J Med Chem. 1992 Nov 13;35(23):4450-4
references.pmid: 1447744
references.citation: Blood. 1993 Jun 15;81(12):3404-13
references.pmid: 8507876
references.citation: Lancet. 1995 Jul 8;346(8967):85-9
references.pmid: 7603218
references.citation: Mol Pharmacol. 1995 Sep;48(3):459-71
references.pmid: 7565626
references.citation: Ann Intern Med. 1996 Mar 1;124(5):469-76
references.pmid: 8602704
references.citation: Adv Enzyme Regul. 1998;38:135-52
references.pmid: 9762351
references.citation: Ann Surg. 2005 May;241(5):829-36; discussion 836-8
references.pmid: 15849519
references.citation: Mol Cancer Ther. 2007 Feb;6(2):404-17
references.pmid: 17308042
references.citation: Oncology. 2007;73(1-2):9-20
references.pmid: 18334829
references.citation: Mol Pharmacol. 2008 Sep;74(3):854-62
references.pmid: 18524888
references.citation: JAMA. 2010 Jun 23;303(24):2486-94
references.pmid: 20571015
references.citation: Eur J Cancer. 2012 Apr;48(6):813-9
references.pmid: 21782418
references.citation: Colorectal Dis. 2012 Jul;14(7):797-803
references.pmid: 21689340
references.citation: Ann Oncol. 2012 Oct;23(10):2479-516
references.pmid: 23012255